GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Retained Earnings

Antibe Therapeutics (TSX:ATE) Retained Earnings : C$-145.50 Mil (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Antibe Therapeutics's retained earnings for the quarter that ended in Dec. 2023 was C$-145.50 Mil.

Antibe Therapeutics's quarterly retained earnings declined from Jun. 2023 (C$-136.28 Mil) to Sep. 2023 (C$-141.29 Mil) and declined from Sep. 2023 (C$-141.29 Mil) to Dec. 2023 (C$-145.50 Mil).

Antibe Therapeutics's annual retained earnings declined from Mar. 2021 (C$-85.96 Mil) to Mar. 2022 (C$-111.02 Mil) and declined from Mar. 2022 (C$-111.02 Mil) to Mar. 2023 (C$-130.49 Mil).


Antibe Therapeutics Retained Earnings Historical Data

The historical data trend for Antibe Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Retained Earnings Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -40.33 -59.67 -85.96 -111.02 -130.49

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -126.94 -130.49 -136.28 -141.29 -145.50

Antibe Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Antibe Therapeutics  (TSX:ATE) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Antibe Therapeutics (TSX:ATE) Business Description

Traded in Other Exchanges
Address
15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
Executives
Daniel Marcel Legault Senior Officer
Alain Wilson Senior Officer
John Lawrence Wallace Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines